MALARIA VACCINES MARKET ANALYSIS

Malaria Vaccines Market, By Vaccine Type (Pre-Erythrocytic Vaccines, Erythrocytic Vaccines, and Multi-Antigen Vaccines), By Agent (Plasmodium Falciparum, Plasmodium Vivax, and Anopheles Species), By Age (Pediatric and Adult), By Distribution Channel (Public and Private), By End Users (Hospitals, Specialty Clinics, Community Health Centers, and Homecare), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Published In : Feb 2025
Code : CMI37
Pages :166
Formats :
Excel and PDF
Industry : Pharmaceutical

Malaria Vaccines Market Size and Trends

The Global Malaria Vaccines Market is estimated to be valued at USD 620.0 Mn in 2025 and is expected to reach USD 1,432.7 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of 12.7% from 2025 to 2032.

Key Takeaways of the Malaria Vaccines Market:

Based on vaccine type, the pre-erythrocytic vaccines segment is expected to contribute the highest share of the market with 42.6% in 2025
Based on agent, the Plasmodium Falciparum segment is expected to contribute the highest share of the market with 46.1% in 2025
Based on age, the pediatric segment is expected to contribute the highest share of the market with 52.8% in 2025
North America is expected to top the global market with 38.9% share, followed by Asia Pacific with 28.2% share in 2025

Market Overview:

Factors, such as rising global incidences of malaria, growing government support, and increasing R&D funding by private and public organizations, are expected to drive the demand for novel and effective malaria vaccines. Currently, there is no highly effective vaccine for malaria however few vaccines are under development which shows promise. If approved, these vaccines could help reduce malaria burden globally and complement other preventive and therapeutic measures. Furthermore, initiatives by WHO to eradicate malaria by 2030 will further contribute towards the growth of this market. Developme